360. A First-in-Human Study to Assess the Safety, Tolerability, Pharmacokinetics, and Neutralization Profile of Two Long-Acting Anti-SARS-CoV-2 Monoclonal Antibodies

BACKGROUND: COVID-19 remains a significant risk to the immunodeficient population, which is more vulnerable to severe consequences and less likely to mount a protective immune response following vaccination. Monoclonal antibodies (mAbs) have been effective and safe, but the emergence of omicron and...

Descripción completa

Detalles Bibliográficos
Autores principales: Asiago, Josephat, Albizem, Moetaz, Tieu, Holly L, Stecco, Kathryn, Moullan, Norman, Fenwick, Craig, Lin, Kai, Poffenbarger, Lauren, Lengsfeld, Thomas, Liu, David W, Hock, Björn M, Venkayya, Rajeev, Bhuyan, Prakash
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Abstract
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10677639/
http://dx.doi.org/10.1093/ofid/ofad500.430

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10677639/
http://dx.doi.org/10.1093/ofid/ofad500.430

Ejemplares similares